Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Melanoma/Skin Cancer
•
Dermatology
What clinical criteria do you use to start oral nicotinamide for chemoprevention?
Related Questions
Should JAK inhibitors be avoided in patients with a recent history of melanoma?
What have you found more effective, blue-light or red-light photodynamic therapy (PDT)?
What factors do you weigh most heavily in the selection of radiotherapy versus topical treatments for lentigo maligna in a patient who is not a surgical candidate?
Under what circumstances would brachytherapy be preferred over electron therapy for treating skin cancers?
How would you approach the radiation treatment of multiple recurrent lentigo maligna on the sole of the foot in an active patient not desiring further surgery?
How should the use of the DecisionDx-Melanoma test be integrated into clinical practice to potentially avoid sentinel lymph node biopsy?
How do you manage new-onset vitiligo in a patient on immune checkpoint inhibitors?
How have you used Hedgehog pathway inhibitors as neoadjuvant/adjuvant therapies?
How would you manage BCC to the left cheek after only half of a radiation course was completed three months ago and non-operative management is preferred?
In what situations would you recommend adjuvant radiation therapy for patients with locally advanced and/or recurrent basal cell carcinoma that receive vismodegib followed by surgery?
